Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Shorts Increased By 11.09%

May 16, 2018 - By Kristin Houston

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Corporate Logo

It was noted an increase on Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s short interest with 11.09%. FINRA issued in May ANTH’s total 2.14 million short interest. The up change of 11.09% from 1.92M shares was reported. With Average volume 770,900, ANTH’s former position will take 3 days to recover.

The stock decreased 2.83% or $0.0088 during the last trading session, touching $0.3026.Anthera Pharmaceuticals, Inc. has volume of 270,082 shares. Since May 16, 2017 ANTH has declined 90.50% and is downtrending. ANTH underperformed the S&P 500 by 102.05%.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.The firm is worth $7.08 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy.Last it reported negative earnings.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Coverage

Total analysts of 3 have positions in Anthera Pharmaceuticals (NASDAQ:ANTH) as follows: 1 rated it a “Buy”, 1 with “Sell” and 1 with “Hold”. The positive are 33%. Since January 22, 2018 according to StockzIntelligence Inc Anthera Pharmaceuticals has 5 analyst reports. The company rating was downgraded by Piper Jaffray on Monday, March 12. In Monday, January 22 report Piper Jaffray maintained it with “Buy” rating and $4.0 target. The company rating was maintained by Jefferies on Tuesday, February 13. On Tuesday, March 6 the firm earned “Hold” rating by Jefferies.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.